初步证据表明磷酸替罗非班（帕利昔单抗）对实体瘤具有生物活性。
Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
机构信息
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
出版信息
Vet Comp Oncol. 2012 Sep;10(3):194-205. doi: 10.1111/j.1476-5829.2011.00275.x. Epub 2011 Jun 1.
The purpose of this study was to provide an initial assessment of the potential biologic activity of toceranib phosphate (Palladia®, Pfizer Animal Health, Madison, NJ, USA) in select solid tumours in dogs. Cases in which toceranib was used to treat dogs with apocrine gland anal sac adenocarcinoma (AGASACA), metastatic osteosarcoma (OSA), thyroid carcinoma, head and neck carcinoma and nasal carcinoma were included. Clinical benefit (CB) was observed in 63/85 (74%) dogs including 28/32 AGASACA [8 partial response (PR), 20 stable disease (SD)], 11/23 OSAs (1 PR and 10 SD), 12/15 thyroid carcinomas (4 PR and 8 SD), 7/8 head and neck carcinomas [1 complete response (CR), 5 PR and 1 SD] and 5/7 (1 CR and 4 SD) nasal carcinomas. For dogs experiencing CB, the median dose of toceranib was 2.8 mg kg(-1) , 36/63 (58.7%) were dosed on a Monday/Wednesday/Friday basis and 47/63 (74.6%) were treated 4 months or longer. Although these data provide preliminary evidence that toceranib exhibits CB in dogs with certain solid tumours, future prospective studies are necessary to define its true activity.
本研究旨在初步评估磷酸替罗尼泊（百奥明，辉瑞动物保健，麦迪逊，新泽西州，美国）在犬某些实体肿瘤中的潜在生物学活性。纳入了使用替罗尼泊治疗犬的大汗腺肛门囊腺癌（AGASACA）、转移性骨肉瘤（OSA）、甲状腺癌、头颈部癌和鼻癌的病例。在 85 例犬中观察到临床获益（CB），包括 32 例 AGASACA [8 例部分缓解（PR），20 例稳定疾病（SD）]、23 例 OSA [1 例 PR 和 10 例 SD]、15 例甲状腺癌[4 例 PR 和 8 例 SD]、8 例头颈部癌[1 例完全缓解（CR），5 例 PR 和 1 例 SD]和 7 例鼻癌[1 例 CR 和 4 例 SD]。对于经历 CB 的犬，替罗尼泊的中位剂量为 2.8mg/kg，36/63（58.7%）犬采用周一/周三/周五给药方案，47/63（74.6%）犬治疗 4 个月或更长时间。尽管这些数据初步表明替罗尼泊在犬某些实体肿瘤中表现出 CB，但仍需进一步前瞻性研究来确定其真正的活性。
Zotero 插件